Literature DB >> 8820506

Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis.

S K Bhaumik1, V Kher, P Arora, P K Rai, M Singhal, A Gupta, R Pandey, R K Sharma.   

Abstract

We analyzed the case records of 19 patients diagnosed to have drug-induced acute interstitial nephritis to assess the clinical profile and role of steroids in renal recovery, and to correlate histological features to outcome. Patients with underlying glomerular diseases, malignancy, obstructive nephropathy, or systemic infections were excluded. Nonsteroidal anti-inflammatory drugs alone accounted for 6 cases (group A), whereas antibiotics were the major offender in the remaining patients (group B). In 13/19 (69%) cases, renal failure was severe enough to require dialytic support. Overall 14/19 (74%) of the patients recovered normal renal function within 6 weeks of withdrawal of the offending drugs. Neither the extent of renal recovery nor the time required for it was altered by oral steroids. Tubular atrophy and interstitial fibrosis adversely affected renal recovery. Oliguria, tubular necrosis, interstitial edema, and the density/distribution of interstitial infiltrate did not have any effect on the rate/extent of renal recovery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820506     DOI: 10.3109/08860229609052779

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  14 in total

Review 1.  Drug-induced acute interstitial nephritis.

Authors:  Mark A Perazella; Glen S Markowitz
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

2.  Kidney injuries related to ipilimumab.

Authors:  Hassane Izzedine; Victor Gueutin; Chems Gharbi; Christine Mateus; Caroline Robert; Emilie Routier; Marina Thomas; Alain Baumelou; Philippe Rouvier
Journal:  Invest New Drugs       Date:  2014-04-01       Impact factor: 3.850

Review 3.  Differentiating Acute Interstitial Nephritis from Acute Tubular Injury: A Challenge for Clinicians.

Authors:  Dennis G Moledina; Chirag R Parikh
Journal:  Nephron       Date:  2019-06-14       Impact factor: 2.847

Review 4.  Renal Toxicities of Targeted Therapies.

Authors:  Anum Abbas; Mohsin M Mirza; Apar Kishor Ganti; Ketki Tendulkar
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

5.  Acute interstitial nephritis due to proton pump inhibitors.

Authors:  K Sampathkumar; R Ramalingam; A Prabakar; A Abraham
Journal:  Indian J Nephrol       Date:  2013-07

6.  Biopsy proven acute interstitial nephritis after treatment with moxifloxacin.

Authors:  Christos Chatzikyrkou; Iyas Hamwi; Christian Clajus; Jan Becker; Carsten Hafer; Jan T Kielstein
Journal:  BMC Nephrol       Date:  2010-08-23       Impact factor: 2.388

Review 7.  Drug-Induced Acute Kidney Injury.

Authors:  Mark A Perazella; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-10       Impact factor: 10.614

8.  Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis.

Authors:  Dennis G Moledina; F Perry Wilson; Lidiya Kukova; Wassim Obeid; Randy Luciano; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Mark A Perazella; Lloyd G Cantley; Chirag R Parikh
Journal:  Nephrol Dial Transplant       Date:  2021-09-27       Impact factor: 5.992

Review 9.  Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician.

Authors:  Mark A Perazella
Journal:  Clin Nephrol       Date:  2014-06       Impact factor: 0.975

10.  Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey.

Authors:  Sarah Wente-Schulz; Marina Aksenova; Atif Awan; Cahyani Gita Ambarsari; Francesca Becherucci; Francesco Emma; Marc Fila; Telma Francisco; Ibrahim Gokce; Bora Gülhan; Matthias Hansen; Timo Jahnukainen; Mahmoud Kallash; Konstantinos Kamperis; Sherene Mason; Antonio Mastrangelo; Francesca Mencarelli; Bogna Niwinska-Faryna; Michael Riordan; Rina R Rus; Seha Saygili; Erkin Serdaroglu; Sevgin Taner; Rezan Topaloglu; Enrico Vidal; Robert Woroniecki; Sibel Yel; Jakub Zieg; Lars Pape
Journal:  BMJ Open       Date:  2021-05-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.